NCT02133001 – A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Subjects Who Are Assessed to be at Imminent Risk for Suicide Posted on March 4, 2021 by tsuperadmin -
NCT03039192 – A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide Posted on March 1, 2021 by tsuperadmin -
NCT02422186 – A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects With Treatment-resistant Depression Posted on March 1, 2021 by tsuperadmin -
NCT02418585 – A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression Posted on March 1, 2021 by tsuperadmin -
NCT02417064 – A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression Posted on March 1, 2021 by tsuperadmin -
Placebo-controlled evaluation of galantamine in the treatment of Alzheimer’s disease: Evaluation of safety and efficacy under a slow titration regimen Posted on January 10, 2018 by tsuperadmin -
A group comparative, placebo-controlled, double-blind trial of the efficacy and safety of galantamine hydrobromide, 7.5 mg (6 mg galantamine base) TID, 10 mg (8 mg galantamine base) TID and 15 mg (12 mg galantamine base) TID taken orally for 12 weeks in patients with a diagnosis of senile dementia of the Alzheimer’s type Posted on October 13, 2017 by tsuperadmin -
NCT00082602 – Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer’s Disease Posted on September 20, 2017 by tsuperadmin -
Attainment of treatment goals by people with Alzheimer’s disease receiving galantamine: a randomized controlled trial Posted on September 7, 2017 by tsuperadmin -
NCT00645190 – A Randomized, Double Blind, Active Control, Flexible Dose, Multicenter Study to Evaluate Galantamine HBr in the Treatment of Alzheimer’s Disease: Safety and Effectiveness of an Immediate-release Table Formulation. Posted on September 7, 2017 by tsuperadmin -
The YODA Project